Compare
Gilead Sciences vs Pfizer
MonkScore ranges and fundamentals, side by side
Key facts
Gilead Sciences and Pfizer: key facts
- In fiscal 2025, Gilead Sciences, Inc. reported revenue of $29.4B and net income of $8.5B.
- In fiscal 2025, Pfizer Inc. reported revenue of $62.6B and net income of $7.8B.
- Gilead Sciences, Inc.'s revenue grew 1.9% a year from fiscal 2021 to fiscal 2025.
- Pfizer Inc.'s revenue fell 6.3% a year from fiscal 2021 to fiscal 2025.
- Gilead Sciences, Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- Pfizer Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
- In the twelve months to 30 September 2026, Gilead Sciences, Inc. reported revenue of $31.0B and net income of -$3.9B.
- In the twelve months to 28 June 2026, Pfizer Inc. reported revenue of $63.7B and net income of $4.3B.
Side by side
Gilead Sciences and Pfizer, side by side
Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.
| Figure | Gilead Sciences, Inc.NASDAQ:GILD | Pfizer Inc.NYSE:PFE |
|---|---|---|
| MonkScore | ||
| MonkScore range | 90–100as of October 2026 | 20–30as of October 2026 |
| Sector rank | 39 of 628 in Healthcare | 520 of 628 in Healthcare |
| How this score is madeDisclaimer | ||
| Profile | ||
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Latest fiscal year | ||
| Revenue | $29.4BFY 2025 | $62.6BFY 2025 |
| Net income | $8.5BFY 2025 | $7.8BFY 2025 |
| Free cash flow | $9.5BFY 2025 | $9.1BFY 2025 |
| Operating cash flow | $10.0BFY 2025 | $11.7BFY 2025 |
| Total debt | $24.9BFY 2025 | $67.4BFY 2025 |
| Cash | $7.6BFY 2025 | $1.1BFY 2025 |
| Last 12 months | ||
| Revenue | $31.0Bto 30 September 2026 | $63.7Bto 28 June 2026 |
| Net income | -$3.9Bto 30 September 2026 | $4.3Bto 28 June 2026 |
| Free cash flow | $14.0Bto 30 September 2026 | $11.0Bto 28 June 2026 |
| Operating cash flow | $14.5Bto 30 September 2026 | $13.4Bto 28 June 2026 |
| Total debt | $26.2Bto 30 September 2026 | $63.2Bto 28 June 2026 |
| Cash | $6.4Bto 30 September 2026 | $976.0Mto 28 June 2026 |
Company pages
Each company on its own
MonkStreet provides research, not investment advice.